The Spanish Heart Transplant Registry presents the results of the activity corresponding to 2024, analyzing trends in recipient and donor profiles, the use of mechanical circulatory support, and survival patterns over the past decade.
A randomized US trial aimed to determine whether concomitant tricuspid valve surgery (TVS) at the time of durable left ventricular assist device (LVAD) implantation reduces tricuspid regurgitation (TR) and the incidence of long-term right heart failure (RHF).
This study analyzes data from the ACTION registry to assess whether morbidity and mortality after ventricular assist device (VAD) implantation differ between children with and without congenital heart disease (CHD), and whether outcomes among those with CHD vary according to anatomy (single- vs. biventricular).
This retrospective observational study describes the experience of the binational ANZCORS registry involving 376 pediatric patients who required extracorporeal membrane oxygenation (ECMO) following cardiac surgery.
Single-center retrospective study assessing the utility of omentoplasty in patients with left ventricular assist device (LVAD) infections.
This single-center retrospective observational study presents a case series of pediatric patients with cardiogenic shock managed using the Impella device.
Results from the US heart transplant program between 2016 and 2022, analyzing demographic characteristics, mortality, and 30-day readmissions in heart transplant recipients.
Editorial commentary on novel cannulation strategies in extracorporeal membrane oxygenation (ECMO) recently published in the Journal of Cardiothoracic and Vascular Anesthesia, proposing technical alternatives to standard VA or VV-ECMO support. These alternative approaches may be particularly valuable in cases of complex pathophysiology, high cardiac output, right ventricular failure, or when conventional devices are contraindicated.
Visual and annotated summary of a surgical tutorial video on the explantation of the HeartMate 3 during orthotopic heart transplantation, complemented by recent evidence on surgical approaches, explant techniques, and clinical outcomes.
This substudy of the DanGer Shock trial assessed outcomes associated with the use of Impella CP® for the management of cardiogenic shock (CS) secondary to myocardial infarction (MI) according to patient age.
If you wish to receive our monthly newsletter, containing all the news collected on our portal, please fill in your email address and click on the “Subscribe” button.